Absci Q2 2024 Earnings Report $3.16 +0.17 (+5.69%) (As of 01:15 PM ET) Absci EPS ResultsActual EPS-$0.22Consensus EPS -$0.19Beat/MissMissed by -$0.03One Year Ago EPS-$0.27Absci Revenue ResultsActual Revenue$1.27 millionExpected Revenue$2.05 millionBeat/MissMissed by -$780.00 thousandYoY Revenue GrowthN/AAbsci Announcement DetailsQuarterQ2 2024Date8/14/2024TimeAfter Market ClosesConference Call ResourcesConference CallPress ReleaseABSI Earnings HistoryPowered by Fed Declares War on Americans (Ad)Fed Declares War on Americans Protect your wealth in the coming months… [RUSH MY FREE GUIDE NOW] Absci Earnings HeadlinesAbsci Co. (NASDAQ:ABSI) Receives $8.67 Average PT from AnalystsNovember 26, 2024 | americanbankingnews.comAbsci to Participate in the 36th Annual Piper Sandler Healthcare ConferenceNovember 22, 2024 | markets.businessinsider.comCoins Set to Soar with a Pro-Crypto White HouseCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…December 4, 2024 | Crypto 101 Media (Ad)Absci management to meet virtually with KeyBancNovember 19, 2024 | markets.businessinsider.comAbsci (NASDAQ:ABSI) Stock, Option ChainNovember 15, 2024 | benzinga.comAbsci Corp (ABSI) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial ChallengesNovember 14, 2024 | finance.yahoo.comSee More Absci Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Absci? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Absci and other key companies, straight to your email. Email Address About AbsciAbsci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.View Absci ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report Upcoming Earnings Toronto-Dominion Bank (12/5/2024)Canadian Imperial Bank of Commerce (12/5/2024)Bank of Montreal (12/5/2024)Oracle (12/9/2024)Adobe (12/11/2024)Broadcom (12/12/2024)Costco Wholesale (12/12/2024)Accenture (12/17/2024)Micron Technology (12/18/2024)Paychex (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
